Showing results (131-140 of 153) with videos related to

Sort By:
Pageof 16
Cancer Discovery|November 2, 2023
Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA MutationsAndreas Varkaris, Ferran Fece de la Cruz, Elizabeth E Martin, et al.
Cancer Discovery|December 31, 2016
Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive CholangiocarcinomaLipika Goyal, Supriya K Saha, Leah Y Liu, et al.
Cancer Discovery|January 22, 2014
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuitZehua Zhu, Amir R Aref, Travis J Cohoon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2020
Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal CancersAparna R Parikh, Amikasra Mojtahed, Jaime L Schneider, et al.
Cancer Discovery|January 8, 2026
Acquired on-target alterations drive clinical resistance to p53-Y220C reactivatorsFerran Fece de la Cruz, Andreas Varkaris, Parasvi S Patel, et al.
Cancer Cell|August 29, 2025
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAF<sup>V600E</sup> metastatic colorectal cancerVan K Morris, Christine M Parseghian, Vahid Bahrambeigi, et al.
Nature Cancer|February 5, 2022
Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trialAparna R Parikh, Annamaria Szabolcs, Jill N Allen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2024
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid TumorsRyan B Corcoran, Khanh T Do, Jeong E Kim, et al.
Nature Communications|October 27, 2017
Resistance to checkpoint blockade therapy through inactivation of antigen presentationMoshe Sade-Feldman, Yunxin J Jiao, Jonathan H Chen, et al.
JAMA Oncology|May 31, 2019
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical TrialJanet E Murphy, Jennifer Y Wo, David P Ryan, et al.
Pageof 16